DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Monday. The firm issued a hold rating on the stock.

Separately, HC Wainwright lowered their price target on shares of DBV Technologies from $20.00 to $10.00 and set a buy rating on the stock in a research report on Wednesday, May 8th.

DBV Technologies Trading Down 1.5 %

Shares of DBVT opened at $0.76 on Monday. The firm’s 50-day moving average is $1.09 and its two-hundred day moving average is $1.47. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $3.72. The firm has a market capitalization of $73.33 million, a P/E ratio of -0.90 and a beta of 0.69.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The company had revenue of $1.41 million for the quarter, compared to analyst estimates of $3.20 million. Analysts predict that DBV Technologies will post -1.22 EPS for the current year.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.